Literature DB >> 18712284

Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme.

Camilo E Fadul1, Patrick Y Wen, Lyndon Kim, Jeffrey J Olson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18712284     DOI： 10.1007/s11060-008-9615-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  76 in total

1.  Local chemotherapy with cisplatin-depot for glioblastoma multiforme.

Authors:  Sergey V Sheleg; Eugeny A Korotkevich; Edvard A Zhavrid; Galina V Muravskaya; Arnold F Smeyanovich; Yury G Shanko; Tatsiana L Yurkshtovich; Pavel B Bychkovsky; Sergey A Belyaev
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

2.  O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.

Authors:  Carme Balaña; Jose Luis Ramirez; Miquel Taron; Yannis Roussos; Aurelio Ariza; Rosa Ballester; Carme Sarries; Pedro Mendez; Jose Javier Sanchez; Rafael Rosell
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

3.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.

Authors:  J C Buckner; P J Schomberg; W L McGinnis; T L Cascino; B W Scheithauer; J R O'Fallon; R F Morton; S A Kuross; J A Mailliard; A K Hatfield; J T Cole; P D Steen; A M Bernath
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

5.  Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

Authors:  Ron H J Mathijssen; Floris A de Jong; Ron H N van Schaik; Erin R Lepper; Lena E Friberg; Trinet Rietveld; Peter de Bruijn; Wilfried J Graveland; William D Figg; Jaap Verweij; Alex Sparreboom
Journal:  J Natl Cancer Inst       Date:  2004-11-03       Impact factor: 13.506

6.  Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.

Authors:  Michael Glantz; Marc Chamberlain; Qin Liu; N Scott Litofsky; Lawrence D Recht
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

7.  Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.

Authors:  M Deutsch; S B Green; T A Strike; P C Burger; J T Robertson; R G Selker; W R Shapiro; J Mealey; J Ransohoff; P Paoletti
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

8.  PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.

Authors:  Roland H Goldbrunner; Martin Bendszus; Jeanette Wood; Michael Kiderlen; Masato Sasaki; Jörg-Christian Tonn
Journal:  Neurosurgery       Date:  2004-08       Impact factor: 4.654

9.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

10.  Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme.

Authors:  In Sil Choi; Se Hoon Lee; Tae-You Kim; Jae Seug Bang; Sun Ha Paek; Suzy Kim; Il Han Kim; Dae Seog Heo; Yung-Jue Bang; Dong Gyu Kim; Hee-Won Jung; Noe Kyeong Kim
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130
View more
  8 in total

Review 1.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

Review 2.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

3.  Clinical practice guidelines in the AANS/CNS Section on Tumors: past, present and future directions.

Authors:  Mark E Linskey; Jeffrey J Olson; Laura S Mitchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2014-08-01       Impact factor: 4.130

4.  Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas.

Authors:  Alexandre Roux; Hichem Ammar; Alessandro Moiraghi; Sophie Peeters; Marwan Baroud; Gilles Zah-Bi; Joseph Benzakoun; Eduardo Parraga; Catherine Oppenheim; Chiara Benevello; Fabrice Chretien; Pascale Varlet; Frédéric Dhermain; Edouard Dezamis; Marc Zanello; Johan Pallud
Journal:  Neurosurg Rev       Date:  2021-10-14       Impact factor: 3.042

5.  Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.

Authors:  Sajeel A Chowdhary; Timothy Ryken; Herbert B Newton
Journal:  J Neurooncol       Date:  2015-01-29       Impact factor: 4.130

Review 6.  Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.

Authors:  Lynn S Ashby; Kris A Smith; Baldassarre Stea
Journal:  World J Surg Oncol       Date:  2016-08-24       Impact factor: 2.754

7.  The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible.

Authors:  Jeffrey D Voigt; Gene Barnett
Journal:  Cost Eff Resour Alloc       Date:  2016-03-21

8.  Low concentration of quercetin antagonizes the invasion and angiogenesis of human glioblastoma U251 cells.

Authors:  Yue Liu; Zhen-Gang Tang; Jian-Quan Yang; Yi Zhou; Ling-Hu Meng; Heng Wang; Cai-Li Li
Journal:  Onco Targets Ther       Date:  2017-08-11       Impact factor: 4.147
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.